| Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial 2010 · Prebiotic and probiotic fortified milk (PP) · Children aged 1–4 years in a community setting in India, with no specific diagnosed condition required | 0.019 billion CFU | 2.4 g | 1 year | 312 |
| Effects of synbiotics on necrotizing enterocolitis and full enteral feeding in very low birth weight infants: A double-blind, randomized controlled trial 2024 · Synbiotic group · Preterm neonates with very low birth weight under 1500 g and gestational age under 34 weeks | 2 billion CFU | — | — | 59 |
| Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial 2018 · Synbiotics group · Patients older than 16 years with sepsis requiring mechanical ventilation in the ICU | 3 g | 10 g | 20 days | 35 |
| Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study 2023 · intervention group · Adults aged 18 years or older hospitalized with PCR-confirmed COVID-19 who required more than 48 hours of admission | 1 billion CFU | 200 mg | — | 78 |
| Perioperative synbiotics decrease postoperative complications in periampullary neoplasms: a randomized, double-blind clinical trial 2015 · group S (synbiotics) · Adults undergoing surgery for periampullary neoplasms; age and sex not specified | 8 billion CFU | 200 mg | 2 weeks | 23 |
| A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial 2024 · SIM01 · Adults with post-acute COVID-19 syndrome (PACS), with at least one PACS symptom persisting for 4 weeks or more after confirmed SARS-CoV-2 infection | 20 billion CFU | — | 26 weeks | 232 |
| Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients-A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial 2024 · multi-strain synbiotic group · Female and male patients aged 18–65 years with moderate to severe irritable bowel syndrome | 4.5 billion CFU | — | 12 weeks | 101 |
| Effectiveness of Sterilized Symbiotic Drink Containing Lactobacillus helveticus Comparable to Probiotic Alone in Patients with Constipation-Predominant Irritable Bowel Syndrome 2020 · Group A (symbiotic group) · Adults with constipation-predominant irritable bowel syndrome; age range not reported; both sexes | 350 mL | 5.85 g | 7 days | 79 |
| The effects of LactoCare synbiotic administration on chemotherapy-induced nausea, vomiting, diarrhea, and constipation in children with ALL: A double-blind randomized clinical trial 2023 · LactoCare-treatment group · Children with acute lymphoblastic leukemia receiving maintenance chemotherapy | 10 billion CFU | — | 7 days | 58 |
| Probiotics combined with prebiotics alleviated seasonal allergic rhinitis by altering the composition and metabolic function of intestinal microbiota: a prospective, randomized, double-blind, placebo-controlled clinical trial 2024 · test group (probiotics and prebiotics) · Adults aged 18–65 with seasonal allergic rhinitis lasting more than 1 year and TNSS greater than 4 | 8 g | 60 g | 90 days | 53 |
| Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial 2023 · Group D · Adults aged 18–70 with functional constipation | 19.2 billion CFU | 960 mg | 4 weeks | 50 |
| Functional response to a microbial synbiotic in the gastrointestinal system of children: a randomized clinical trial 2023 · Active synbiotic arm · Children aged 3–17, male and female, with variable weekly bowel movement frequency; some had low-frequency bowel movements or constipation | 10 billion CFU | 6.2 g | 12 weeks | 43 |
| The promising effects of a multi-species synbiotic preparation on metabolic profile in elderly patients with type 2 diabetes and high cardiovascular risk: a randomized, triple-blind, placebo-controlled trial 2025 · Synbiotic group · Men and women aged 65 years or older with type 2 diabetes and high cardiovascular risk | 2 billion CFU | 500 mg | 120 days | 43 |
| Effect of a Multispecies Synbiotic Supplementation on Body Composition, Antioxidant Status, and Gut Microbiomes in Overweight and Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Study 2023 · synbiotic group · Adults aged 18–45 with BMI 23–30 kg/m², classified as overweight or obese | 37 billion CFU | — | 12 weeks | 36 |
| The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study 2020 · synbiotic group · Female and male adults aged 18–60 with moderate or severe diarrhea-predominant irritable bowel syndrome (IBS-D) | 10 billion CFU | 1.89 g | 8 weeks | 35 |
| The effects of synbiotics supplementation on reducing chemotherapy-induced side effects in women with breast cancer: a randomized placebo-controlled double-blind clinical trial 2023 · Synbiotics · Women aged 18 years or older with breast cancer, no metastasis, undergoing neoadjuvant or adjuvant chemotherapy | 2 billion CFU | 42 g | 8 weeks | 34 |
| Effects and Persistence of Bifidobacterium animalis subsp. lactis BL-99 and Fructooligosaccharides on Older Adults with Functional Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial 2025 · synbiotic group · Adults aged 60 years or older with functional constipation by Rome IV criteria and no significant comorbidities | 20 billion CFU | 800 mg | 4 weeks | 34 |
| Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease 2025 · synbiotic group · Adults aged 45–65, both sexes, newly diagnosed with Parkinson's disease, stages 1–4 | 20 billion CFU | 6 g | 90 days | 33 |
| Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis 2016 · synbiotic group · Adults aged 25–74 with biopsy-confirmed nonalcoholic steatohepatitis (NASH); both sexes | 0.2 billion CFU | 8 g | 90 days | 27 |
| Effects of synbiotic supplementation on the components of metabolic syndrome in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial 2024 · Synbiotic + antipsychotic group · Adults aged 18–65 with schizophrenia, BMI ≥23 and at least two metabolic-syndrome criteria, taking antipsychotic drugs | 2 billion CFU | 42 mg | 8 weeks | 27 |
| Effect of yogurt containing polydextrose, Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019: a randomized, double-blind, controlled study in chronic constipation 2014 · Treatment Group (TG) · Adults aged 18–45 years, both sexes, with chronic constipation | 2 billion CFU | 3.6 g | 2 weeks | 26 |
| Effects of probiotic and synbiotic supplementation on ponderal and linear growth in severely malnourished young infants in a randomized clinical trial 2023 · Synbiotic · Infants aged 2–6 months with severe acute malnutrition, recovering from acute illness; both sexes | 8 billion CFU | 3.2 g | 4 weeks | 23 |
| Ameliorating effects of L-carnitine and synbiotic co-supplementation on anthropometric measures and cardiometabolic traits in women with obesity: a randomized controlled clinical trial 2023 · L-carnitine + synbiotic · Women aged 19–49 with obesity (BMI 30–35 kg/m²), without the listed comorbidities | 0.1 billion CFU | 175 mg | 8 weeks | 23 |
| Do synbiotics really enhance beneficial synbiotics effect on defecation symptoms in healthy adults?: Randomized, double-blind, placebo-controlled trial 2022 · Synbiotics · Healthy adults aged 20–60 years, men and women, with bowel movements 2–3 times per week and a tendency to constipation | 10 billion CFU | 1 g | 2 weeks | 22 |
| The effect of a new developed synbiotic yogurt consumption on metabolic syndrome components in adults with metabolic syndrome: a randomized controlled clinical trial 2024 · intervention group · Adults aged 30–50 with metabolic syndrome and BMI 25–35 kg/m² | 0.2 billion CFU | — | 12 weeks | 22 |
| A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal Calprotectin Levels: A Pilot Study 2022 · synbiotic group · Adults with functional diarrhea and fecal calprotectin levels of at least 11.5 mg/kg; mean age 49.8 years | 0.1 billion CFU | 2.4 g | 8 weeks | 20 |
| Comparison of the Effects of Prebiotics and Synbiotics Supplementation on the Immune Function of Male University Football Players 2023 · synbiotic group (SG) · Male university football players; age not reported; healthy student-athletes undergoing high-intensity training | 14 billion CFU | — | 6 weeks | 15 |
| Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years 2006 · Synbiotic group · Children aged 2 years and over with moderate or severe atopic dermatitis and a SCORAD score of at least 15 | 3.6 billion CFU | — | 90 days | — |
| Beneficial effects of a synbiotic supplement on self-perceived gastrointestinal well-being and immunoinflammatory status of healthy adults 2011 · synbiotic product · Healthy adults aged 25–45 years; 20 women and 16 men overall | 2.4 billion CFU | — | 6 weeks | — |
| Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study 2011 · synbiotics treatment group · Patients with mild to moderate ulcerative colitis | 3 g | 5.5 g | 1 year | — |
| Synbiotic in the management of infantile colic: a randomised controlled trial 2014 · synbiotic group · Breastfed infants aged 15–120 days with infantile colic | 1 billion CFU | — | 30 days | — |
| Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults-Randomized Controlled Trial 2016 · LU + B420 · Adults aged 18–65 with overweight or obesity (BMI 28.0–34.9) | 10 billion CFU | 12 g | 26 weeks | — |
| Effect of synbiotic and probiotic supplementation on serum brain-derived neurotrophic factor level, depression and anxiety symptoms in hemodialysis patients: a randomized, double-blinded, clinical trial 2021 · synbiotic · Hemodialysis patients; age and sex not specified | 5 g | 15 g | 12 weeks | — |
| Effect of synbiotic supplementation on migraine characteristics and inflammatory biomarkers in women with migraine: Results of a randomized controlled trial 2021 · synbiotic · Women with migraine | 2 billion CFU | — | 12 weeks | — |
| Effects of Synbiotic Supplementation on Metabolic Syndrome Traits and Gut Microbial Profile among Overweight and Obese Hong Kong Chinese Individuals: A Randomized Trial 2023 · synbiotic supplementation group (SG) · Overweight and obese Hong Kong Chinese individuals aged 20–65 years | 20 billion CFU | 3.4 g | 8 weeks | — |
| Effects of Synbiotic Supplementation on Metabolic Syndrome Traits and Gut Microbial Profile among Overweight and Obese Hong Kong Chinese Individuals: A Randomized Trial 2023 · dietary intervention with synbiotic supplementation group (DSG) · Overweight and obese Hong Kong Chinese individuals aged 20–65 years | 20 billion CFU | 3.4 g | 8 weeks | — |
| A young child formula with Limosilactobacillus reuteri and GOS modulates gut microbiome and enhances bone and muscle development: a randomized trial 2025 · experimental young child formula (EYCF) · Healthy Filipino boys and girls aged 24–36 months | 0.1 billion CFU | — | 26 weeks | 91 |
| Synbiotic as an ameliorating factor in the health-related quality of life in women with polycystic ovary syndrome. A randomized, triple-blind, placebo-controlled trial 2024 · synbiotic group · Women aged 18–45 with newly diagnosed polycystic ovary syndrome (PCOS) | 20 billion CFU | 500 mg | 12 weeks | 28 |
| Effects of a Synbiotic Formula on Functional Bowel Disorders and Gut Microbiota Profile during Long-Term Home Enteral Nutrition (LTHEN): A Pilot Study 2020 · intervention group (IG) · Bedridden adults with neurological disorders receiving long-term home enteral nutrition; average age 75.2 years | 1.01 billion CFU | 375 mg | 120 days | 11 |
| Differential Health Effects on Inflammatory, Immunological and Stress Parameters in Professional Soccer Players and Sedentary Individuals after Consuming a Synbiotic. A Triple-Blinded, Randomized, Placebo-Controlled Pilot Study 2021 · Sedentary participants administered with the synbiotic · Sedentary male students with low physical activity (≤150 min/week) | 1 billion CFU | 200 mg | 30 days | — |
| Differential Health Effects on Inflammatory, Immunological and Stress Parameters in Professional Soccer Players and Sedentary Individuals after Consuming a Synbiotic. A Triple-Blinded, Randomized, Placebo-Controlled Pilot Study 2021 · Professional soccer players administered with the synbiotic · Male professional soccer players competing in the Spanish Second Division B | 1 billion CFU | 200 mg | 30 days | — |
| The effects of synbiotic supplementation on blood pressure and other maternal outcomes in pregnant mothers with mild preeclampsia: a triple-blinded randomized controlled trial 2024 · synbiotic group · Pregnant women aged 24 years or older with mild preeclampsia | 1 billion CFU | — | — | 64 |
| A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women 2025 · SBD111 · Healthy postmenopausal women 1–6 years after menopause, aged about 55 years; some had osteopenia or BMI ≥30 | 95 billion CFU | 1.28 g | 1 year | 144 |
| Efficacy of the Synbiotic Supplementation on the Metabolic Factors in Patients with Metabolic Syndrome: A Randomized, Triple-Blind, Placebo-Controlled Trial 2022 · synbiotic · Adults with metabolic syndrome; age range and sex distribution not specified | 1 billion CFU | 77 g | 12 weeks | 65 |
| Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease 2020 · synbiotic treatment · Adults with proven nonalcoholic fatty liver disease (NAFLD); ages and sex distribution not specified for this arm | 10 billion CFU | 8 g | 1 year | 55 |
| Effect of synbiotic supplementation on immune parameters and gut microbiota in healthy adults: a double-blind randomized controlled trial 2023 · Synbiotic · Healthy adults aged 18–65 years; 66% female in this arm; no stated disease | 0.225 billion CFU | 500 mg | 8 weeks | 53 |
| Impact of Synbiotic Intake on Liver Metabolism in Metabolically Healthy Participants and Its Potential Preventive Effect on Metabolic-Dysfunction-Associated Fatty Liver Disease (MAFLD): A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial 2024 · synbiotic (SYN) · Men aged 20–60 years, metabolically healthy, with BMI 20–34 kg/m² | 2 billion CFU | — | 7 weeks | 45 |
| Evaluation of Lactocare® Synbiotic Administration on the Serum Electrolytes and Trace Elements Levels in Psoriasis Patients: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial Study 2022 · treatment group · Adults aged 18–60 with mild to moderate psoriasis | 2 billion CFU | — | 12 weeks | 32 |
| The effects of synbiotics on indoxyl sulphate level, constipation, and quality of life associated with constipation in chronic haemodialysis patients: a randomized controlled trial 2022 · Synbiotics · Adults over 18 years old with chronic kidney disease on haemodialysis and gastrointestinal complaints including constipation | 10 billion CFU | 60 mg | 60 days | 30 |
| Changes in Gut Microbiota and Systemic Inflammation after Synbiotic Supplementation in Patients with Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 · synbiotic-supplemented group · Women aged 18–60 with systemic lupus erythematosus and gastrointestinal symptoms | 3 billion CFU | 80 mg | 60 days | 23 |
| Consumption of a new developed synbiotic yogurt improves oxidative stress status in adults with metabolic syndrome: a randomized controlled clinical trial 2024 · Intervention group · Adults aged 30–50 with metabolic syndrome and BMI 25–35 kg/m² | 0.2 billion CFU | — | 12 weeks | 22 |
| Synbiotic Lactobacillus acidophilus NCFM and cellobiose does not affect human gut bacterial diversity but increases abundance of lactobacilli, bifidobacteria and branched-chain fatty acids: a randomized, double-blinded cross-over trial 2014 · synbiotic · Healthy volunteers; age and sex not reported. | 1 billion CFU | 5 g | 3 weeks | 18 |
| Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection 2012 · Synbiotic · Adult women with HIV-1 infection taking antiretroviral medication and with blood CD4 count >200 cells/μl | 10 billion CFU | 2.5 g | 4 weeks | 14 |
| Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity 2020 · synbiotic (treatment) group · Adult men and women, mean age 47.4 years, initially overweight or obese (mean BMI 33.5 kg/m²), enrolled in a weight-loss program; participants with gastrointestinal, autoimmune or metabolic diseases and relevant medications were excluded. | 15 billion CFU | 5.5 g | 90 days | 10 |
| In school-aged children a combination of galacto-oligosaccharides and Lactobacillus GG increases bifidobacteria more than Lactobacillus GG on its own 2008 · LGG plus GOS · Healthy school-aged children | 6.5 billion CFU | 2 g | 3 weeks | — |
| Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics 2018 · IVS-1 + GOS · Women and men aged 18–65 years with obesity (BMI 30.0–40.0 kg/m²) | 1 billion CFU | 5 g | 3 weeks | — |
| Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics 2018 · BB-12 + GOS · Women and men aged 18–65 years with obesity (BMI 30.0–40.0 kg/m²) | 1 billion CFU | 5 g | 3 weeks | — |
| A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients 2019 · synbiotic group · Hemodialysis patients; age and sex not reported | 100 mg | — | 8 weeks | — |
| The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID-19 patients: A randomized placebo-controlled trial 2023 · intervention group · Hospitalized patients with confirmed COVID-19 infection; age and sex not specified | 2 billion CFU | — | 2 weeks | — |
| Multi-species synbiotic supplementation increased fecal short chain fatty acids and anti-inflammatory cytokine interleukin-10 in adult men with dyslipidemia; A randomized, double-blind, clinical trial 2024 · synbiotic group · Adult men with dyslipidemia | 60 billion CFU | 10 g | 12 weeks | — |
| Effects of multi-species synbiotic supplementation on circulating miR-27a, miR-33a levels and lipid parameters in adult men with dyslipidaemia; a randomised, double-blind, placebo-controlled clinical trial 2025 · synbiotic · adult men with dyslipidaemia | 60 billion CFU | 10 g | 12 weeks | — |
| Beneficial Effects of Synbiotics on the Gut Microbiome in Individuals with Low Fiber Intake: Secondary Analysis of a Double-Blind, Randomized Controlled Trial 2024 · synbiotic (SYN) group · Male non-smokers aged 20–60 without stated disease; secondary analysis stratified participants by low or high baseline fiber intake | 2 billion CFU | — | 7 weeks | — |
| The impact of synbiotic on serum sCD163/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomized, triple-blind, controlled trial 2024 · synbiotic group · Adults aged 30–70 with chronic heart failure, LVEF <40%, and NYHA class I–III | 30.4 billion CFU | 38.5 mg | 10 weeks | 45 |
| An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients 2021 · Synbiotic (arm S), CKD patients · Adults aged 30–65 with stage IIIb–IV chronic kidney disease, not on dialysis | 4.8 billion CFU | 5 g | 60 days | 13 |
| An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients 2021 · Synbiotic (arm S), healthy volunteers · Healthy adults aged 35–60 | 4.8 billion CFU | 5 g | 60 days | 12 |
| Effects of a Synbiotic on Plasma Immune Activity Markers and Short-Chain Fatty Acids in Children and Adults with ADHD-A Randomized Controlled Trial 2023 · Synbiotic 2000 · Children and adults aged 5–55 with ADHD | 400 billion CFU | 10 g | 9 weeks | — |